References
- Xu L, Wang L, Li K, Zhang Z, Sun H, Yang X. Nicorandil prior to primary percutaneous coronary intervention improves clinical outcomes in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2019;13:1389–1400. doi:10.2147/DDDT.S195918
- Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005;112(9):1284–1288. doi:10.1161/CIRCULATIONAHA.104.53032916116055
- Feng C, Liu Y, Wang L, Niu D, Han B. Effects of early intracoronary administration of nicorandil during percutaneous coronary intervention in patients with acute myocardial infarction. Heart Lung Circ. 2018;28(6):858–865. doi:10.1016/j.hlc.2018.05.097
- Fujiwara T, Matsunaga T, Kameda K, et al. Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction. Heart Vessels. 2007;22(5):303–309. doi:10.1007/s00380-007-0975-z17879021
- Feng C, Han B, Liu Y, et al. Effect of nicorandil administration on myocardial microcirculation during primary percutaneous coronary intervention in patients with acute myocardial infarction. Postepy Kardiol Interwencyjnej. 2018;14(1):26–31. doi:10.5114/aic.2018.7435229743901